HIGHLIGHTS
- who: Bader Bashrahil from the University of Naples Federico II, Italy have published the article: The efficacy and safety of lebrikizumab monotherapy for the management of moderate-to-severe atopic dermatitis: A systematic review and meta-analysis, in the Journal: (JOURNAL)
- what: The second regimen included Eligibility criteria the systematic review and meta-analysis exclusively included RCTs that compared lebrikizumab against a placebo in patients with moderate-to-severe AD who are older than 12 years. Subgroup analysis in this study showed an enormously important point regarding the effect of different regimens of lebrikizumab.
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.